ERLOTINIB WITH CHEMOTHERAPY + CHEMOTHERAPY ONLY
Phase 3Terminated 0 views this week 0 watching💤 Quiet
Interest: 32/100
32
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedIndication / Disease
NSCLC Patients With EGFR Activating Mutation
Conditions
NSCLC Patients With EGFR Activating Mutation
Trial Timeline
Jun 1, 2014 → Sep 1, 2015
NCT ID
NCT02178397About ERLOTINIB WITH CHEMOTHERAPY + CHEMOTHERAPY ONLY
ERLOTINIB WITH CHEMOTHERAPY + CHEMOTHERAPY ONLY is a phase 3 stage product being developed by Roche for NSCLC Patients With EGFR Activating Mutation. The current trial status is terminated. This product is registered under clinical trial identifier NCT02178397. Target conditions include NSCLC Patients With EGFR Activating Mutation.
What happened to similar drugs?
7 of 20 similar drugs in NSCLC Patients With EGFR Activating Mutation were approved
Approved (7) Terminated (3) Active (11)
Hype Score Breakdown
Clinical
17
Activity
0
Company
15
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT02178397 | Phase 3 | Terminated |
Competing Products
20 competing products in NSCLC Patients With EGFR Activating Mutation